临床试验与研发进展 - MT-3724在重度预处理的B细胞淋巴瘤患者中进行的1期/1b研究显示，最大耐受剂量（MTD）为50 µg/kg，评估的剂量包括5、10、20、50、75和100 µg/kg[16] - 在MT-3724的临床试验中，38%的客观反应率（ORR），在最大耐受剂量下ORR为60%，包括2个完全反应（CR）和1个部分反应（PR）[17] - MT-3724的开发策略包括针对复发-难治性弥漫性大B细胞淋巴瘤（R-R DLBCL）患者的单药治疗，计划招募最多100名患者[19] - MT-3724的临床开发包括与来那度胺和吉西他滨联合使用的研究，显示出初步的耐受性和疗效证据[19] - 1期研究中，MT-3724在低血清RTX水平的患者中显示出2个完全代谢反应（CMR）和2个部分反应（PR）[17] - MT-3724在临床试验中观察到深度和持久的剂量依赖性B细胞耗竭，显示出良好的耐受性[16] - 公司正在进行MT-3724的单药活性和耐受性验证，针对重度复发/耐药患者群体[64] 新产品与技术 - 2代ETBs（如MT-5111）具有增强的效力和更好的安全性，体外效力（IC50）达到皮克到亚皮克摩尔级别[24] - MT-5111的主要机制是通过酶促破坏核糖体，针对HER2阳性细胞的效力达到皮摩尔级别[27] - 2代ETBs的治疗指数在治疗经验丰富的患者中显著提高，达到5倍[24] - MT-6402在PD-L1+肿瘤细胞中表现出强效，直接杀伤肿瘤细胞的机制独立于肿瘤微环境条件[53] - 2020年，MT-6402的IND申请预计将进行，涉及抗原播种的机制[61] - 公司计划在2020年进行CTLA4的早期开发工作，预计将进行领先选择[58] 现金储备与财务状况 - 目前的现金储备足以支持公司运营至2022年，无需额外的业务发展[4] 其他重要信息 - TAK-169在NHPs中的HNSTD为750 mcg/kg，而MT-3724为150 mcg/kg[46] - TAK-169在临床前模型中，即使在daratumumab存在的情况下，仍能有效内化并杀死低或高表达CD38的细胞[46] - TAK-169在患者样本中表现出活性，包括daratumumab耐药的患者[46] - TAK-169的主要机制是通过酶促破坏核糖体，针对CD38+细胞的pM效力[46] - 2nd-Gen ETB的de-immunized SLTA载荷减少了先天和适应性免疫反应[44] - CD38靶向药物的机制不同，TAK-169通过直接细胞杀伤（酶促核糖体失活）而非间接CDC细胞杀伤[48]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3409596 (State or other jurisdiction of ...

临床试验与产品研发 - MT-3724在重度预处理的B细胞淋巴瘤患者中显示出38%的客观反应率（ORR），包括2例完全反应（CR）和2例部分反应（PR）[14] - MT-3724的最大耐受剂量（MTD）为50 µg/kg，剂量限制性毒性（DLTs）为非生命威胁的2/3级事件[14] - MT-3724的临床开发包括单药治疗和与其他药物的联合治疗，计划招募多达100名患者[15] - MT-5111是一种针对HER2的第二代ETB，具有pM级别的效力，能够有效内化[23][31] - TAK-169是一种针对CD38的第二代ETB，显示出在小鼠模型中的活性，HNSTD为750 mcg/kg[36] - MT-6402对PD-L1阳性肿瘤细胞具有强效，直接杀伤肿瘤细胞的机制与肿瘤微环境条件无关[45] - MT-6402的抗肿瘤机制包括核糖体破坏和抗原播种[49] - MT-6402的抗原播种机制预计将在2020年进行IND申请[52] - MT-6402在PD-L1阳性肿瘤中的临床试验正在进行中[52] - 预计2020年将进行CTLA4的领先开发工作[49] 财务状况与战略合作 - 当前现金储备足以支持公司运营至2022年，无需额外的业务发展[5] - 公司与Takeda和Vertex建立了战略合作关系，进行多靶点合作和股权投资[5] 未来展望 - 预计2020年将提交PD-L1 ETB的IND申请[5] - MT-5111的剂量递增研究中获得了初步数据，验证了平台在实体肿瘤中的应用[57] - MT-3724在重度复发/难治患者中显示出单药活性和耐受性[56] - TAK-169在低或高表达CD38的肿瘤细胞中有效内化并摧毁[38] - 现有CMV特异性T细胞在持续再激活CMV的情况下经历“记忆膨胀”，不易疲惫[43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (State or other jurisdiction of incorporation or organization) 9301 Amberglen Blvd, Suite 100, Austin TX 78729 78729 (Address of principal executive office) (Zi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3409596 (State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3409596 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. FORM 10-Q (Exact name of registrant as specified in its charter) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 94-3409596 (State or other jurisdiction of incorporation or organization) For the quarterly period ended March 31, 2019 9301 Amberglen Blvd Suite 100 Austin, TX 78729 (Address of pri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32979 MOLECULAR TEMPLATES, INC. (Exact name of registrant as specified in its charter) Delaware 94-3409596 (State or other jurisdict ...